(NYSE American: NSRX) Notched A Major Milestone With Positive Topline Results From Key Study

We're watching a chart closely...

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (NYSE American: NSRX) Notched A Major Milestone With Positive Topline Results From Key Study *Click Here To Get Our Alerts Faster Via SMS* May 6th Greetings Readers, We're watching a chart closely... With a Wednesday close above multiple technical levels (including its 20-Day SMA and 13-Day EMA), this NYSE American profile's chart may be signaling support growing. Following a move over the last week+ of 32% from a low of $2.41 to high of $3.20 Wednesday, steady buzz could be building in early May. And with the global epinephrine market projected to grow from $2.66Bn in 2026 to $5.46Bn by 2034, this under-the-radar company is pursuing a faster, more intuitive approach to emergency response. Here's where things get good: this company is fresh off positive Phase 2 topline results representing a giant milestone achieved. Mix in a low float under 6Mn shares and Zacks SCR taking notice with a key report, this NYSE American idea is surging up Thursday's watchlist: Nasus Pharma Ltd. (NYSE American: NSRX) Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’ intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. And based on 5 potential catalysts we've discovered, (NYSE American: NSRX) tops our watchlist Thursday. Take a look: #1. A Float Of This Small Nature Could Create An Environment For Potential Volatility. #2. Positive Results Represent A Major Milestone As Top Line Data Roles Out From Key Phase 2 Clinical Study. #3. Zacks SCR Points Its Focus Towards NSRX With An Explosive Report. #4. Could Chart Support Be Developing At Multiple Technical Levels? #5. The Company's CEO Believes Nasus Pharma Is Well Positioned For Multiple Clinical Inflection Points In 2026. But more on those in a second... Founded by life sciences entrepreneurs and clinicians, Nasus Pharma is advancing therapies for anaphylaxis, opioid overdose, poisoning, seizure, and other medical emergencies. The Nasax® Platform Proprietary Nasax Platform Enables Superior Drug Absorption Powder formulation can reach all parts of the nasal cavity. The greater intranasal absorption area enables faster delivery and higher maximal drug concentration compared to liquid formulations. NS002: Intranasal Epinephrine NS002 is Nasus Pharma’s epinephrine intranasal powder candidate in development for the treatment of anaphylaxis. With phase 2 data demonstrating faster and higher absorption than the EpiPen®, NS002 is poised to transform a market underserved by the current bulky needle-based autoinjectors and nasal sprays with a short shelf life. NS002: Designed to Address the Limitations of Intramuscular Epinephrine NS002: Summary of Phase 2 Results NS002 Could Be a Compelling Alternative to Epinephrine Autoinjectors NS002 reached the hemodynamic therapeutic plasma threshold faster than the EpiPen® Maximum epinephrine absorption (tmax) achieved significantly faster compared to EpiPen® Nasax powder was well tolerated with transient mild symptoms No findings at the nasal examinations No serious adverse events NS002: Clear Roadmap to NDA (New Drug Application) Following FDA guidance based on the 505(b)(2) regulatory pathway Demonstration of comparable PK/PD to EpiPen® only requirement for regulatory approval Pivotal trial expected to initiate Q4 2026 Short and cost-effective clinical development Nasus Pharma Pipeline: Robust Asset Pipeline Setting Up Potential for Long Term Growth Nasus Pharma is advancing a portfolio of powder-based intranasal therapies designed to address life-threatening emergencies.  Their proprietary Nasax® platform delivers rapid, reliable absorption and predictable pharmacokinetics, creating opportunities across multiple acute indications. Grab Sources And Learn More Here: NSRX Website. NSRX Presentation. -----  And as we mentioned previously, (NYSE American: NSRX) has multiple potential catalysts on our radar. Check them out: #1. NSRX Potential Catalyst - A Float Of This Small Nature Could Create An Environment For Potential Volatility. According to info from the Yahoo Finance website, NSRX has a fairly low float. The website reports this profile to have roughly 5.5Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If the company provides positive news during the first half of 2026, could it help provide a breakout spark when paired with this volatility potential? ----- #2. NSRX Potential Catalyst - Positive Results Represent A Major Milestone As Top Line Data Roles Out From Key Phase 2 Clinical Study. Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4% of subjects receiving NS002 reached the threshold compared to 64.6% with EpiPen® NS002 continued to demonstrate a favorable safety profile with no serious adverse events reported and comparable pharmacodynamic response to EpiPen® across all participants Pivotal study initiation planned for fourth quarter of 2026 ... TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced positive top line results from its Phase 2 clinical study of NS002, the Company's investigational intranasal epinephrine powder formulation for the treatment of anaphylaxis. The comprehensive analysis demonstrated that NS002 achieved significantly faster and higher early epinephrine absorption compared to intramuscular EpiPen® autoinjector. The Company plans to initiate its pivotal clinical study in fourth quarter of 2026. The open-label Phase 2 study enrolled 50 healthy adults with a history of allergic rhinitis. All subjects received a single and repeat dose of NS002 and intramuscular EpiPen® with and without a nasal allergic challenge (“NAC”). This robust study design provided comprehensive data supporting NS002's clinical utility across multiple administration scenarios that patients may encounter during actual anaphylactic emergencies. "We've successfully demonstrated NS002's differentiated and potentially superior product profile compared to traditional epinephrine autoinjectors," said Dan Teleman, Chief Executive Officer of Nasus Pharma. "NS002 was specifically engineered for superior epinephrine delivery, powered by our proprietary Nasax® powder platform, and designed as a needle-free, easy to use and carry device. The compelling top line data significantly strengthens our conviction that NS002 has the potential to become a leading product in anaphylaxis treatment. These positive results represent a major milestone for Nasus Pharma as we advance NS002 towards the pivotal study and future marketing applications. We remain on track to initiate our pivotal study in the fourth quarter of 2026, bringing us closer to delivering this potentially life-saving innovation to patients worldwide." ... Read the full article here. ----- #3. Zacks SCR Points Its Focus Towards NSRX With An Explosive Report. In March, Zacks SCR, shared a fully-detailed report on (NYSE American: NSRX). Important recent and future milestones from the report: NP007 Phase II Interim Readout – March 2026 NS002 Investigation New Drug (IND) submission – 3Q:26 Target presentation at allergy and anaphylaxis conferences (AAAAI & ACAAI) – 2026/2027 Publication of data in a respected journal – 2026/2027 Launch NS002 pivotal study – 4Q:26 Pivotal study readout – 1Q:27 New Drug Application (NDA) submission to the FDA – 2Q:27 ----- #4. NSRX Potential Catalyst - Could Chart Support Be Developing At Multiple Technical Levels? Take a look at NSRX's 3-month chart from close Wednesday: With a close at $3.15, NSRX finished ab above 4 key technical chart levels in its: 5-Day Simple Moving Average (SMA) 20-Day SMA 5-Day Exponential Moving Average (EMA) 13-Day EMA If support is growing at those 4 levels, it could act as building blocks towards a continued vertical move. ----- #5. NSRX Potential Catalyst - The Company's CEO Believes Nasus Pharma Is Well Positioned For Multiple Clinical Inflection Points In 2026. Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update Recent Phase 2 topline results demonstrate NS002’s potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study planned for Q4 2026 Company advancing pipeline assets NS003 (Ondansetron for chemotherapy-induced nausea and vomiting) and NS004 (metabolic) toward first-in-human studies expected to start in the second half of 2026, significantly expanding the Company’s intranasal product portfolio into additional high value therapeutic areas Company well funded through planned NS002 pivotal study and potential NDA submission TEL AVIV, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the filing of its annual report on Form 20-F for the year ended December 31, 2025, and provided a business update highlighting recent Phase 2 results for NS002 and upcoming clinical milestones. "With positive Phase 2 data for NS002 and a strong cash position, we believe Nasus is well positioned to deliver on multiple clinical inflection points in 2026," said Dan Teleman, Chief Executive Officer of Nasus Pharma. "Following the compelling topline Phase 2 results of NS002, we are advancing our intranasal epinephrine powder formulation towards a pivotal study planned to initiate in the fourth quarter of this year. The Company is well-funded to complete NS002’s pivotal study and see through a potential NDA filing. In addition, we plan to progress our earlier pipeline assets, Ondansetron for chemotherapy induced nausea and vomiting, and NS004 targeting metabolic disorders, into first-in-human studies in the second half of the year and are also advancing NS005 targeting cardiovascular diseases. We believe our pipeline of innovative intranasal products, leveraging our proprietary powder platform technology, can deliver significant clinical benefits to patients and could unlock substantial value to our shareholders. We are committed to executing on this vision.” ... Early Pipeline Nasus is advancing its earlier-stage pipeline programs, which leverage the Company’s proprietary intranasal powder platform: NS003 – Ondansetron for chemotherapy-induced nausea and vomiting NS004 – targeting metabolic disorders NS005 – targeting cardiovascular diseases All programs are currently in preclinical development, with first-in-human Phase 1 studies expected to initiate in the second half of 2026 for NS003 and NS004, supporting the continued expansion of the Company’s intranasal product portfolio. ... Read the full article here. ----- (NYSE American: NSRX) Recap - 5 Potential Catalysts Lead The Way #1. A Float Of This Small Nature Could Create An Environment For Potential Volatility. #2. Positive Results Represent A Major Milestone As Top Line Data Roles Out From Key Phase 2 Clinical Study. #3. Zacks SCR Points Its Focus Towards NSRX With An Explosive Report. #4. Could Chart Support Be Developing At Multiple Technical Levels? #5. The Company's CEO Believes Nasus Pharma Is Well Positioned For Multiple Clinical Inflection Points In 2026. ----- Coverage is officially launched on Nasus Pharma Ltd. (NYSE American: NSRX). Be on watch for updates heading out shortly. Talk again soon. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 05/06/2026 and ending on 05/07/2026 to publicly disseminate information about (NSRX:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (NSRX:US). Please see important disclosure information here:https://stockwirenews.com/disclosure/nsrx-r4i6w/#details

SWN Media | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice